Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Reports Fourth Quarter and Full Year 2017 Financial Results
MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017; Total Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its
View HTML
Toggle Summary Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018
View HTML
Toggle Summary Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced an agreement with the Institute of Integrative Biology at the
View HTML
Toggle Summary Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines
View HTML
Toggle Summary Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from
View HTML
Toggle Summary Anika Reports Third Quarter 2017 Financial Results
Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in
View HTML
Toggle Summary Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III
View HTML
Toggle Summary Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the appointment of Thomas M.
View HTML
Toggle Summary Anika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that regulatory authorities in Australia granted approval to
View HTML
Toggle Summary Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017 ,
View HTML